We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $160M
1-Year Est. Return 517.12%
This Fund
S&P 500
This Quarter Est. Return
+15.77%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$113M
AUM Growth
+$12.4M
Cap. Flow
+$8.07M
Cap. Flow %
7.13%
Top 10 Hldgs %
79.99%
Holding
35
New
11
Increased
3
Reduced
4
Closed
7

Top Buys

Rank Stock Value
1
HRTX icon
Heron Therapeutics
HRTX
+$8.05M
2
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$3.67M
3
OPTN
OptiNose
OPTN
+$3.34M
4
CTLT
CATALENT, INC.
CTLT
+$2.72M
5
IMTX icon
Immatics
IMTX
+$2.59M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$4.92M
2
ADMA icon
ADMA Biologics
ADMA
+$3.91M
3
HCSG icon
Healthcare Services Group
HCSG
+$3.6M
4
LNTH icon
Lantheus
LNTH
+$3.08M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.83M

Sector Composition

Rank Sector Weight
1 Healthcare 82.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHRS icon
26
Coherus Oncology
CHRS
$181M
$654K 0.58%
+82,605
New +$636K
LMDX
27
DELISTED
LumiraDx Limited Common Shares
LMDX
$514K 0.45%
571,428
– –
TERN
28
DELISTED
Terns Pharmaceuticals
TERN
$108K 0.1%
+10,646
New +$70.9K
ASRT
29
DELISTED
Assertio
ASRT
– –
-15,651
Closed -$533K
BCRX icon
30
BioCryst Pharmaceuticals
BCRX
$2.71B
– –
-225,000
Closed -$2.83M
FEZ icon
31
PUT
State Street SPDR EURO STOXX 50 ETF
FEZ
$4.55B
– –
-500,000
Closed -$15.4M
GKOS icon
32
Glaukos
GKOS
$11B
– –
-6,896
Closed -$367K
NYXH
33
Nyxoah
NYXH
$158M
– –
-79,021
Closed -$498K
STLN
34
Starling Oncology, Inc. Common Stock
STLN
$644M
– –
-548,841
Closed -$2.54M
ZYME icon
35
Zymeworks
ZYME
$1.77B
– –
-234,902
Closed -$1.45M
1
2

Similar funds

BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM
SMF
Sterling Manor Financial Saratoga Springs, New York $160M AUM 13.84% 1-Year Est. Return
LCA
Legend Capital Advisors New York $160M AUM
SGCM
Sanchez Gaunt Capital Management Reno, Nevada $160M AUM
RP
RIHO Partners Tucson, Arizona $159M AUM
PCC
Perry Creek Capital New York $160M AUM 3.05% 1-Year Est. Return
RCWM
Royal Capital Wealth Management Carmel, Indiana $161M AUM 18.42% 1-Year Est. Return

Velan Capital Investment Management's Q4 2022 Portfolio in Review

As of Q4 2022, Velan Capital Investment Management held 35 positions worth $113M, up 12% from $101M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Velan Capital Investment Management deployed $8.07M of net new capital in Q4 2022, opening 11 new positions and adding to 3 existing holdings. Its largest new stake was Heron Therapeutics: 2,500,000 shares worth $6.25M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 84% a quarter earlier.

On the sell side, the largest reduction was Immunocore, an estimated $4.92M trimmed.

  • Velan Capital Investment Management's largest Q4 2022 buy was Heron Therapeutics: 2,500,000 shares worth $6.25M.
  • Velan Capital Investment Management added most to OptiNose in Q4 2022, an estimated $3.34M increase.
  • Velan Capital Investment Management's biggest Q4 2022 reduction was Immunocore, cutting an estimated $4.92M.
  • Velan Capital Investment Management fully exited BioCryst Pharmaceuticals in Q4 2022, selling an estimated $2.83M.
  • Velan Capital Investment Management's ten largest holdings make up 80% of its $113M portfolio in Q4 2022.
  • Velan Capital Investment Management opened 11 new positions and closed 7 in Q4 2022.
  • Velan Capital Investment Management's portfolio value rose 12% quarter-over-quarter to $113M.

Based on Velan Capital Investment Management's 13F filing for Q4 2022, filed 13 Feb 2023.